Aerovate Therapeutics
Aerovate Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare cardiopulmonary diseases. The company’s lead product candidate, AV-101, is an inhaled formulation of imatinib designed to address pulmonary arterial hypertension (PAH), a progressive and life-threatening condition. By leveraging scientific expertise and a patient-centric approach, Aerovate Therapeutics aims to advance differentiated treatments that improve patient outcomes and address significant unmet medical needs. The company’s pipeline reflects a commitment to rigorous research and development, targeting diseases with limited therapeutic options. Aerovate Therapeutics collaborates with healthcare professionals and stakeholders to drive innovation in the biopharmaceutical industry, striving to deliver impactful solutions for patients with serious cardiopulmonary disorders.
